Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-05-27 AGM Information
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice of the Annual General Meeting (AGM) for Ocumension Therapeutics, detailing the date, location, agenda items including adoption of audited financial statements, re-election of directors, appointment of auditors, and approval of share issuance and repurchase mandates. It is clearly a meeting notice rather than the actual meeting materials or financial reports. The presence of resolutions to be voted on and instructions for shareholders to appoint proxies further confirms this is an AGM notice. Therefore, the document fits the category of AGM Information (AGM-R). The document length and content support this classification with high confidence.
2021-05-27 English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; PROPOSED GRANTING OF SPECIFIC MANDATE TO ISSUE UNLISTED WARRANTS AND
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed circular from Ocumension Therapeutics dated May 28, 2021, containing a notice of the Annual General Meeting (AGM) scheduled for June 29, 2021. It includes proposals for granting general mandates to issue and repurchase shares, re-election of directors, and granting specific mandates related to warrants. The document also contains a form of proxy and explanatory statements related to the AGM. The presence of detailed agenda items, proxy forms, and voting instructions indicates this is a circular related to the AGM rather than the AGM presentation materials themselves. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it is sent to shareholders to provide information and request votes for the meeting. It is not an Annual Report (10-K), Earnings Release (ER), or Management Report (MDA), nor is it a simple announcement or notice of report publication. Therefore, the appropriate classification is PSI with high confidence.
2021-05-27 English
VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL AUTHORIZATION FOR INITIATING A PHASE III CLINICAL TRIAL OF OT-101 ACCEPTED IN UNITED KINGDOM
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the acceptance of a clinical trial authorization for a Phase III clinical trial in the UK. It is an update on business progress and regulatory acceptance, not a financial report or detailed management discussion. The document is relatively short (2831 characters) and serves to inform shareholders and investors about a specific business development. There is no financial data, no voting results, no management changes, no earnings information, and no detailed report attached or referenced. This fits best into the category of a Regulatory Filing (RNS), which is a general regulatory announcement or compliance document that does not fit into other specific categories.
2021-05-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ocumension Therapeutics, detailing changes in issued share capital and share buybacks. It includes specific data on share issues, share repurchases, and confirmations related to compliance with listing rules. The content focuses on disclosures about share capital changes and repurchases rather than financial performance, management changes, or earnings. This type of document is a regulatory disclosure related to share capital changes and repurchases, fitting the category of Transaction in Own Shares (POS). The document length is sufficient and contains detailed transactional data, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2021-05-13 English
VOLUNTARY ANNOUNCEMENT IND APPLICATION RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the acceptance of an investigational new drug application for a Phase III clinical trial. It is an update on business progress and regulatory acceptance, not a financial report or detailed management discussion. The document is short (2849 characters) and serves to inform shareholders and investors about a clinical trial application, with no financial data or detailed report content. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the strict sense but a voluntary business update. Given the nature and length, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-05-11 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/09/2020. The content focuses on share capital changes, share issuance, and related confirmations. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange, consistent with a Major Shareholding Notification or Share Issue/Capital Change. However, since it reports monthly movements in securities and share capital, it aligns best with Share Issue/Capital Change filings. Therefore, the document is classified as a Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement.
2021-05-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.